Product logins

Find logins to all Clarivate products below.


Stacey Chang-Douglass

Head of Health Economics and Director in Consulting

Stacey is Head of Health Economics and Director in Consulting at Clarivate.

Stacey has nearly 15 years’ experience in health economics and outcome research at consultancies and at NICE. She specialises in economic modelling to support HTA submissions, global model development and country adaptation and national guidelines across an extensive range of therapeutic areas.

Prior to joining Clarivate, Stacey held senior positions at different consultancies, as Principal Consultant at Parexel, Director in Health Economics at Lumanity and Research Scientist at Evidera, where she led multidisciplinary projects for economic modelling and evidence synthesis. She provided quality assurance for deliverables and technical guidance for the internal team and provided strategic insights to ensure a long-term partnership with the clients.

Stacey serves as a standing committee member at the Medical Technologies Advisory Committee at NICE since 2022. Stacey also serves as a reviewer of funding proposals and HTA reports for NIHR in the UK since 2015.

Stacey holds an MSc in International Health Policy from London School of Economics and a PhD in Health Sciences from the University of York, which focused on outcome measurements in economic evaluations.

Latest news

News April 28, 2026
Clarivate Introduces Nexus Connect, the First Institutional AI Gateway to Trusted Research and Learning

Nexus Connect provides a single, university-branded connector inside AI chat agents, giving students and researchers seamless access to scholarly resources and services. LONDON, UK — April 28, 2026: Clarivate Plc…

News April 27, 2026
Clarivate Report Reveals Top Global Trademark Portfolios

Amazon Technologies, L’Oréal, IGT and Glaxo Group / GSK among the largest trademark portfolio owners across jurisdictions London, U.K. April 27, 2026: Clarivate Plc (NYSE:CLVT), a leading global provider of…

News April 15, 2026
Clarivate to Report First Quarter 2026 Results on April 29, 2026

London, U.K., April 15, 2026 – (PR Newswire) – Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced it will report its financial results for the first…

Related resources

How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.
Managing uncertainty for medicine in Washington Managing uncertainty for medicine in Washington
Blog May 15, 2025
Managing uncertainty for medicine in Washington
Clinical research Early drug development research Market Access Pharma Portfolio strategy Research Research and development Research commercialization Research evaluation and management
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Blog April 2, 2025
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Market Access Pharma Portfolio strategy Regulatory Research commercialization
Five Medtech Trends to Watch in 2025 Five Medtech Trends to Watch in 2025
Blog February 11, 2025
Five Medtech Trends to Watch in 2025
Medical technology Medtech Medtech Resource Center